Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past

Apr 25 2018

• By Mandy Jackson

Syringes stuck in a dartboard

Related Content

New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests

Apr 15 2018

US Launch Of Sensipar Generics May Await Patent Case Even After FDA Approval

Mar 14 2018

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

Dec 02 2017

Response Rates Rule In CGRP Inhibitor Migraine Studies

Jun 12 2017

Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Nov 13 2017

Amgen Invests In Deals, Share Buybacks And Manufacturing As Sales Dip

Feb 02 2018

Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab

Feb 08 2018

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

Apr 12 2018

Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs

Sep 02 2015

Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales

Aug 31 2016

Related Companies

Amgen, Inc.

Novartis AG

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Sanofi

Regeneron Pharmaceuticals, Inc.

Express Scripts Holding Company

Additional Topics

Pricing Strategies Launches Sales & Earnings Commercial Neurology BioPharmaceutical

More from Drug Pricing

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window